ArticleAdvanced nanobiomed research2026
Mesoporous Silica Nanoparticles With Customized Drug Ratio/Loading for Effective Treatment of Gemcitabine-Resistant Pancreatic Tumors.
Article in Advanced nanobiomed research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Magnetothermally Responsive Mesoporous Silica Nanocarriers: Materials Design, Thermoresponsive Gates and Controlled Drug Release.Nanomaterials (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal cancers, with a 5-year survival rate below 13% and limited treatment options due to rapid metastasis and pronounced chemoresistance. Gemcitabine (Gem) remains a first-line chemotherapy agent; however, its clinical efficacy is hindered by poor cellular uptake, incomplete activation, and acquired drug resistance. To address these limitations, we develop redox-responsive mesoporous silica nanoparticles (MSNs) for the mono- and codelivery of Gem and Cisplatin (cisPt). In this work, we tune the loading and ratio of Gem and cisPt within MSNs. To evaluate the therapeutic potential of MSN-based delivery system in Gem-resistant (GR) PDAC cell lines, we establish murine (GR-KCM) and human (GR-BxPC3) cell models and further evaluate the efficacy in highly GR human cell lines (AsPC1 and HPAFII). In vitro studies demonstrate that Gem-MSNs (10%wt) and Gem-cisPt-MSN (10:9%wt) exhibit the strongest cytotoxicity, even in GR models. Notably, the combination Gem-cisPt-MSN (18:9%wt) induces pronounced S-phase cell cycle arrest, apoptosis, and reactive oxygen species. These findings underscore the potential of MSN-based drug delivery systems to enhance chemotherapy efficacy in treatment-refractory PDAC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.